Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Mapping the global distribution of Buruli ulcer: a systematic review with evidence consensus.

Simpson H, Deribe K, Tabah EN, Peters A, Maman I, Frimpong M, Ampadu E, Phillips R, Saunderson P, Pullan RL, Cano J.

Lancet Glob Health. 2019 Jul;7(7):e912-e922. doi: 10.1016/S2214-109X(19)30171-8.

2.

Photocurrent spectra from PbS photovoltaic infrared detectors using silver nanowires as plasmonic nano antenna electrodes.

Kim J, Ampadu EK, Choi WJ, Oh E.

Nanotechnology. 2019 Feb 15;30(7):075201. doi: 10.1088/1361-6528/aaf194. Epub 2018 Nov 16.

PMID:
30523862
3.

Implementing active community-based surveillance-response system for Buruli ulcer early case detection and management in Ghana.

Ahorlu CSK, Okyere D, Ampadu E.

PLoS Negl Trop Dis. 2018 Sep 12;12(9):e0006776. doi: 10.1371/journal.pntd.0006776. eCollection 2018 Sep.

4.

Laboratory confirmation of Buruli ulcer cases in Ghana, 2008-2016.

Yeboah-Manu D, Aboagye SY, Asare P, Asante-Poku A, Ampah K, Danso E, Owusu-Mireku E, Nakobu Z, Ampadu E.

PLoS Negl Trop Dis. 2018 Jun 5;12(6):e0006560. doi: 10.1371/journal.pntd.0006560. eCollection 2018 Jun.

5.

Landscape and environmental influences on Mycobacterium ulcerans distribution among aquatic sites in Ghana.

Pileggi SM, Jordan H, Clennon JA, Whitney E, Benbow ME, Merritt R, McIntosh M, Kimbirauskas R, Small P, Boakye D, Quaye C, Qi J, Campbell L, Gronseth J, Ampadu E, Opare W, Waller LA.

PLoS One. 2017 Apr 24;12(4):e0176375. doi: 10.1371/journal.pone.0176375. eCollection 2017.

6.

Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.

Adu EJ, Ampadu E.

Int J Mycobacteriol. 2015 Jun;4(2):138-42. doi: 10.1016/j.ijmyco.2015.03.006. Epub 2015 Apr 18.

7.

Reply to "compliance with antimicrobial therapy for buruli ulcer".

Phillips RO, Sarfo FS, Abass MK, Frimpong M, Ampadu E, Forson M, Amoako YA, Thompson W, Asiedu K, Wansbrough-Jones M.

Antimicrob Agents Chemother. 2014 Oct;58(10):6341. doi: 10.1128/AAC.03874-14. No abstract available.

8.

Enhancing Buruli ulcer control in Ghana through social interventions: a case study from the Obom sub-district.

Ahorlu CK, Koka E, Yeboah-Manu D, Lamptey I, Ampadu E.

BMC Public Health. 2013 Jan 22;13:59. doi: 10.1186/1471-2458-13-59.

9.

Sero-epidemiology as a tool to screen populations for exposure to Mycobacterium ulcerans.

Yeboah-Manu D, Röltgen K, Opare W, Asan-Ampah K, Quenin-Fosu K, Asante-Poku A, Ampadu E, Fyfe J, Koram K, Ahorlu C, Pluschke G.

PLoS Negl Trop Dis. 2012 Jan;6(1):e1460. doi: 10.1371/journal.pntd.0001460. Epub 2012 Jan 10.

10.

Combining PCR with microscopy to reduce costs of laboratory diagnosis of Buruli ulcer.

Yeboah-Manu D, Asante-Poku A, Asan-Ampah K, Ampadu ED, Pluschke G.

Am J Trop Med Hyg. 2011 Nov;85(5):900-4. doi: 10.4269/ajtmh.2011.11-0362.

11.

The impact of immigration on the development of adolescent schizophrenia.

Ampadu E.

J Child Adolesc Psychiatr Nurs. 2011 Aug;24(3):161-7. doi: 10.1111/j.1744-6171.2011.00290.x. Review.

PMID:
21810132
12.

Health services for Buruli ulcer control: lessons from a field study in Ghana.

Ackumey MM, Kwakye-Maclean C, Ampadu EO, de Savigny D, Weiss MG.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1187. doi: 10.1371/journal.pntd.0001187. Epub 2011 Jun 21.

13.
14.

Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.

Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, Lartey A, Tetteh I, Wansbrough-Jones M.

Antimicrob Agents Chemother. 2010 Sep;54(9):3678-85. doi: 10.1128/AAC.00299-10. Epub 2010 Jun 21.

15.

Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.

Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS.

Lancet. 2010 Feb 20;375(9715):664-72. doi: 10.1016/S0140-6736(09)61962-0. Epub 2010 Feb 3.

PMID:
20137805
16.

Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.

Sarfo FS, Phillips RO, Ampadu E, Sarpong F, Adentwe E, Wansbrough-Jones M.

Clin Vaccine Immunol. 2009 Jan;16(1):61-5. doi: 10.1128/CVI.00235-08. Epub 2008 Nov 12.

17.

Distribution of Mycobacterium ulcerans in buruli ulcer endemic and non-endemic aquatic sites in Ghana.

Williamson HR, Benbow ME, Nguyen KD, Beachboard DC, Kimbirauskas RK, McIntosh MD, Quaye C, Ampadu EO, Boakye D, Merritt RW, Small PL.

PLoS Negl Trop Dis. 2008 Mar 26;2(3):e205. doi: 10.1371/journal.pntd.0000205.

18.

Buruli ulcer, Nigeria.

Chukwuekezie O, Ampadu E, Sopoh G, Dossou A, Tiendrebeogo A, Sadiq L, Portaels F, Asiedu K.

Emerg Infect Dis. 2007 May;13(5):782-3. No abstract available.

19.

A stepwise approach to the laboratory diagnosis of Buruli ulcer disease.

Bretzel G, Siegmund V, Nitschke J, Herbinger KH, Thompson W, Klutse E, Crofts K, Massavon W, Etuaful S, Thompson R, Asamoah-Opare K, Racz P, Vloten F, van Berberich C, Kruppa T, Ampadu E, Fleischer B, Adjei O.

Trop Med Int Health. 2007 Jan;12(1):89-96.

20.

Buruli ulcers: an emerging health problem in Ghana.

Kwyer TA, Ampadu E.

Adv Skin Wound Care. 2006 Nov-Dec;19(9):479-86. No abstract available.

PMID:
17132950
21.

Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism.

Stienstra Y, van der Werf TS, Oosterom E, Nolte IM, van der Graaf WT, Etuaful S, Raghunathan PL, Whitney EA, Ampadu EO, Asamoa K, Klutse EY, te Meerman GJ, Tappero JW, Ashford DA, van der Steege G.

Genes Immun. 2006 Apr;7(3):185-9.

PMID:
16395392
22.

Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients.

Stienstra Y, van Roest MH, van Wezel MJ, Wiersma IC, Hospers IC, Dijkstra PU, Johnson RC, Ampadu EO, Gbovi J, Zinsou C, Etuaful S, Klutse EY, van der Graaf WT, van der Werf TS.

Trop Med Int Health. 2005 Dec;10(12):1251-7.

23.

Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klustse E, Owusu-Boateng J, Amedofu GK, Awuah P, Ampadu E, Amofah G, Asiedu K, Wansbrough-Jones M.

Antimicrob Agents Chemother. 2005 Aug;49(8):3182-6.

24.

Reliability and validity of the Buruli ulcer functional limitation score questionnaire.

Stienstra Y, Dijkstra PU, Van Wezel MJ, Van Roest MH, Beets M, Zijlstra I, Johnson RC, Ampadu EO, Gbovi J, Zinsou C, Etuaful S, Klutse EY, Van der Graaf WT, Van der Werf TS.

Am J Trop Med Hyg. 2005 Apr;72(4):449-52.

PMID:
15827284
25.

Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission.

Hospers IC, Wiersma IC, Dijkstra PU, Stienstra Y, Etuaful S, Ampadu EO, van der Graaf WT, van der Werf TS.

Trans R Soc Trop Med Hyg. 2005 Mar;99(3):196-201.

PMID:
15653121
26.

Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana.

Westenbrink BD, Stienstra Y, Huitema MG, Thompson WA, Klutse EO, Ampadu EO, Boezen HM, Limburg PC, van der Werf TS.

Clin Diagn Lab Immunol. 2005 Jan;12(1):125-9.

27.

Development of a questionnaire assessing Buruli ulcer-induced functional limitation.

Stienstra Y, Dijkstra PU, Guédénon A, Johnson RC, Ampadu EO, Mensah T, Klutse EY, Etuaful S, Deepak S, Van Der Graaf WT, Van Der Werf TS.

Am J Trop Med Hyg. 2004 Mar;70(3):318-22.

PMID:
15031524

Supplemental Content

Loading ...
Support Center